Renal Mass Imaging

Cross-sectional imaging — chiefly multiphase contrast-enhanced CT — is the linchpin for characterising renal masses, distinguishing benign cysts from solid neoplasms, and stratifying surgical risk. This topic threads together the Bosniak classification, enhancement physics, the histological subtypes of renal cell carcinoma (RCC), fat-containing lesions like angiomyolipoma, and the paediatric Wilms tumour — a recurrent NEET PG flavour combining radiology with oncology.

The cardinal principle: enhancement

A renal mass is "enhancing" — and therefore presumed neoplastic until proven otherwise — when its attenuation rises by a defined Hounsfield unit (HU) threshold after intravenous iodinated contrast.

High-yield: An increase of ≥ 20 HU between unenhanced and contrast-enhanced CT is the accepted cut-off for definite enhancement (true solid mass). 10–20 HU is equivocal/indeterminate (pseudo-enhancement vs true). < 10 HU = no enhancement (a simple cyst).

Pseudo-enhancement is a CT artefact in which small intrarenal cysts (especially < 1.5 cm, surrounded by avidly enhancing parenchyma) appear to gain 10–20 HU due to beam-hardening and partial-volume effects. MRI (subtraction images) resolves this dilemma because it is not subject to the same artefact.

Attenuation change after contrast	Interpretation
< 10 HU	No true enhancement → simple/benign cyst
10–20 HU	Indeterminate (pseudo-enhancement possible) → MRI/follow-up
≥ 20 HU	True enhancement → solid enhancing mass (neoplasm)

A baseline unenhanced HU also categorises content: simple fluid is 0–20 HU; macroscopic fat is negative (−10 to −100 HU); haemorrhage/protein is hyperdense (> 20 HU, often 40–90 HU).

Multiphase CT protocol — the investigation of choice

A dedicated renal mass CT protocol (CT urography / triple-phase) is the workhorse. The standard phases:

1. Unenhanced (non-contrast) — establishes baseline density; detects fat, calcification, haemorrhage; the reference for measuring enhancement.
2. Corticomedullary phase (~25–40 s) — cortex enhances brightly, medulla lags. Best for vascular mapping and depicting hypervascular clear-cell RCC; but small medullary tumours can be missed.
3. Nephrographic phase (~80–100 s) — homogeneous parenchymal enhancement; best phase to detect and characterise renal masses because lesions stand out against uniform parenchyma.
4. Excretory/urographic phase (~3–15 min) — opacified collecting system; assesses urothelial involvement and pelvicalyceal anatomy.

High-yield: The nephrographic phase is the single most sensitive phase for detecting a renal mass. The corticomedullary phase best demonstrates hypervascularity (clear-cell RCC) and vascular/venous anatomy.

Flow of mass work-up: Incidental renal lesion on USG/CT → dedicated multiphase CT → measure unenhanced HU and post-contrast change → fat present? → if yes → AML; if no, enhancing solid? → if ≥ 20 HU → RCC pathway (stage + subtype) → if cystic → apply Bosniak classification → manage accordingly.

Bosniak classification of renal cysts

The Bosniak system (originally CT-based; a 2019 update incorporates MRI) stratifies cystic renal lesions by malignant potential using wall/septal thickness, calcification, enhancement, and number of septa.

Class	Features	Malignancy risk	Management
I	Hairline-thin wall, no septa/calcification, no enhancement, water density	~0%	Benign — no follow-up
II	Few thin (< 1 mm) septa, fine calcification; ≤ 3 cm hyperdense non-enhancing cyst	~0%	Benign — no follow-up
IIF	Multiple thin septa, minimal smooth wall/septal thickening, "perceived" (not measurable) enhancement; > 3 cm hyperdense cyst	~5%	Surveillance imaging
III	Thick/irregular walls or septa with measurable enhancement	~50%	Surgery/resection
IV	Class III features plus enhancing soft-tissue nodular components	~90%	Surgery (treat as malignant)

High-yield: The pivotal split is between Bosniak IIF (follow-up: "F" = follow-up) and Bosniak III (operate). The presence of measurable enhancement in thick septa/walls pushes a lesion from IIF to III. Calcification per se does not upgrade a cyst — it is the enhancing soft tissue that matters.

Mnemonic for management: "I and II ignore, IIF follow, III and IV go to the OR."

Renal cell carcinoma — subtypes and enhancement patterns

RCC accounts for ~90% of adult renal malignancies. The three common subtypes have characteristic enhancement signatures that are heavily tested.

Subtype	Frequency	Enhancement	Key imaging clue	Prognosis
Clear cell	~70%	Avid, heterogeneous, hypervascular; often > 80–100 HU corticomedullary; rapid wash-out	Necrosis, haemorrhage, "ball-type" exophytic mass; venous invasion	Worst of the common three (but most common)
Papillary	~10–15%	Hypovascular, homogeneous, low-level (often < 30 HU)	Often hypoenhancing, may be hyperdense on NCCT; frequently haemorrhagic; can be bilateral/multifocal	Better than clear cell
Chromophobe	~5%	Intermediate, homogeneous enhancement; central stellate scar may mimic oncocytoma	Spoke-wheel pattern less than oncocytoma; arises from intercalated cells	Best prognosis of the three

High-yield: Clear cell = hypervascular and heterogeneous; papillary = hypovascular and homogeneous. A renal mass with brisk corticomedullary enhancement and rapid wash-out is clear-cell RCC until proven otherwise.

Clinical pearls layered into questions:

• Von Hippel–Lindau (VHL) disease → multiple, bilateral clear-cell RCC + renal cysts + phaeochromocytoma + CNS/retinal haemangioblastomas.
• Hereditary papillary RCC and Birt–Hogg–Dubé (chromophobe/oncocytoma) are syndromic associations.
• Tuberous sclerosis → multiple angiomyolipomas (and renal cysts).
• RCC classically invades the renal vein → IVC as a tumour thrombus — MRI/CT venous phase is critical for surgical planning; right atrial extension changes the operative approach.
• The paraneoplastic quartet — polycythaemia (EPO), hypercalcaemia (PTHrP), hypertension (renin), Stauffer syndrome (non-metastatic hepatic dysfunction).

Staging (TNM essentials): T1 ≤ 7 cm (T1a ≤ 4 cm, T1b 4–7 cm) confined to kidney; T2 > 7 cm confined; T3 into renal vein/perinephric fat (within Gerota fascia); T4 beyond Gerota fascia or into ipsilateral adrenal. T1a tumours favour partial nephrectomy / nephron-sparing surgery.

Oncocytoma — the benign mimic

Renal oncocytoma is a benign tumour that closely imitates chromophobe RCC. Classic (but not reliable enough to avoid surgery) features: a central stellate scar and a spoke-wheel arterial pattern on angiography/CT.

High-yield: A central stellate scar with spoke-wheel vascularity suggests oncocytoma, but because it cannot be confidently distinguished from chromophobe RCC on imaging, most are resected/biopsied. Do not call a solid enhancing mass "benign" on imaging alone.

Angiomyolipoma (AML) — the fat-containing lesion

AML is the commonest benign solid renal neoplasm, composed of abnormal angio (vessels), myo (smooth muscle) and lipoma (fat). Detection of macroscopic (bulk) fat within a non-calcified renal mass is essentially diagnostic.

High-yield: Identification of macroscopic fat (attenuation −10 HU or lower, typically −20 to −100 HU) within a renal mass on CT — in the absence of calcification — is diagnostic of angiomyolipoma. RCC almost never contains macroscopic fat; if a fatty mass contains calcification, suspect RCC instead.

Pitfalls and pearls:

• Fat-poor (lipid-poor) AML (~5%) lacks measurable macroscopic fat and is indistinguishable from RCC on CT — may need MRI (loses signal on out-of-phase / India-ink artefact at fat–water interface) or biopsy.
• Multiple bilateral AMLs → think tuberous sclerosis (also: facial angiofibromas, cortical tubers, subependymal nodules, cardiac rhabdomyoma, lymphangioleiomyomatosis).
• Wünderlich syndrome = spontaneous retroperitoneal haemorrhage from a large AML (risk rises when > 4 cm, due to aneurysmal vessels) — an indication for prophylactic embolisation or resection.

Mnemonic: AML = "A Mass of Lipid" → look for negative HU.

MRI and contrast ultrasound — problem-solving tools

• MRI is the choice when CT is equivocal, in patients with iodinated-contrast allergy or renal impairment (using caution with gadolinium), to characterise haemorrhagic/proteinaceous cysts, to confirm pseudo-enhancement, and to detect microscopic fat (chemical-shift/out-of-phase signal drop in clear-cell RCC and fat-poor AML).
• Contrast-enhanced ultrasound (CEUS) depicts septal/nodular enhancement in cystic lesions without nephrotoxic contrast — useful in renal failure.
• DMSA/functional studies are not for masses (they assess cortical function/scarring).

Wilms tumour (nephroblastoma) — paediatric imaging

The classic paediatric renal mass, Wilms tumour, is the most common renal malignancy of childhood (peak 3–4 years). It arises from metanephric blastema.

High-yield: A large, heterogeneous, well-circumscribed intrarenal mass with a "claw sign" (a beak of normal renal parenchyma cupping the mass) in a child 1–5 years old is Wilms tumour. It displaces rather than encases vessels and rarely crosses the midline — the principal differentiator from neuroblastoma.

Feature	Wilms tumour	Neuroblastoma
Origin	Kidney (intrarenal, claw sign)	Adrenal/sympathetic chain (extrarenal, suprarenal)
Age	~3–4 yr	< 2 yr (younger)
Calcification	Uncommon (~10%)	Common (~90%, coarse/stippled)
Vessels	Displaces	Encases ("draped aorta" sign)
Midline crossing	Rare	Frequently crosses midline
Vascular invasion	Renal vein/IVC tumour thrombus	Less
Markers	—	↑ Urinary VMA/HVA

Wilms associations (syndromes): WAGR (Wilms, Aniridia, Genitourinary anomalies, Range of developmental delay; WT1 deletion 11p13), Beckwith–Wiedemann (hemihypertrophy, macroglossia; 11p15), and Denys–Drash. Imaging work-up: USG first → contrast CT/MRI of abdomen for local staging and contralateral kidney → chest CT for pulmonary metastases (lung is the commonest metastatic site). Staging follows NWTS/COG systems; treatment is multimodal (nephrectomy + chemotherapy ± radiotherapy).

High-yield: Always image the contralateral kidney in Wilms (bilateral disease = stage V) and screen the chest for lung metastases.

Other entities and key differentials

• Multilocular cystic nephroma — a benign multiseptated cystic mass with bimodal distribution (young boys and middle-aged women); classically herniates into the renal pelvis.
• Renal abscess / infected cyst — clinical context (fever, pyuria), rim enhancement, restricted diffusion; not a tumour.
• Renal lymphoma — multiple bilateral homogeneous hypovascular masses or perinephric soft tissue; usually secondary; encases vessels without thrombosis.
• Urothelial (TCC) of renal pelvis — central, infiltrative, "faceless kidney"; preserves reniform shape; best seen on excretory phase as a filling defect.
• Renal infarct — wedge-shaped non-enhancing area with a cortical rim sign (preserved subcapsular enhancement).
• Metastasis to kidney — lung and breast primaries; often multiple.

Differentiator	Pointer
Macroscopic fat, no calcium	Angiomyolipoma
Fat with calcification	Suspect RCC
Hypervascular, heterogeneous, vein invasion	Clear-cell RCC
Hypovascular, homogeneous, multifocal	Papillary RCC
Central scar, spoke-wheel	Oncocytoma / chromophobe RCC
Thick enhancing septa in cyst	Bosniak III/IV → operate
Child, claw sign, displaces vessels	Wilms
Infant, calcified, encases vessels, crosses midline	Neuroblastoma

Recently asked / exam angle

• The ≥ 20 HU enhancement cut-off for a solid renal mass — a perennial single-best-answer item.
• Matching RCC subtype to vascularity: clear cell = hypervascular, papillary = hypovascular — frequently asked as an image-based or descriptive MCQ.
• Bosniak III vs IIF management — which class warrants surgery (III/IV) versus follow-up (IIF).
• Macroscopic fat = angiomyolipoma, and the > 4 cm bleeding risk / Wünderlich syndrome association.
• Wilms vs neuroblastoma table differentiators (claw sign, vessel displacement vs encasement, midline crossing, calcification, age).
• Nephrographic phase = best phase to detect a renal mass; corticomedullary phase = best for hypervascularity and venous mapping.
• VHL → bilateral clear-cell RCC; tuberous sclerosis → multiple AMLs.
• Cortical rim sign (infarct) and claw/beak sign (intrarenal origin) as named radiological signs.

Rapid revision

1. Enhancement ≥ 20 HU post-contrast = true solid renal mass (neoplasm); < 10 HU = simple cyst; 10–20 HU = indeterminate.
2. Nephrographic phase best detects masses; corticomedullary phase best shows hypervascularity and vascular anatomy.
3. Clear-cell RCC (commonest, ~70%) = hypervascular, heterogeneous, renal-vein/IVC invasion, worst prognosis of the three.
4. Papillary RCC = hypovascular, homogeneous, often multifocal/bilateral, can be hyperdense on NCCT.
5. Chromophobe RCC = intermediate homogeneous enhancement, best prognosis; central scar may mimic oncocytoma.
6. Bosniak: I/II benign, IIF follow-up, III/IV operate; enhancing soft tissue — not calcification — upgrades a cyst.
7. Macroscopic fat (negative HU) without calcification = angiomyolipoma; fat + calcium → suspect RCC.
8. AML > 4 cm bleeds → Wünderlich syndrome; multiple bilateral AMLs → tuberous sclerosis.
9. Oncocytoma: central stellate scar + spoke-wheel vessels; cannot be reliably separated from chromophobe RCC.
10. Wilms tumour: child 3–4 yr, intrarenal claw sign, displaces vessels, rarely crosses midline; lung is commonest metastasis.
11. Neuroblastoma: younger infant, suprarenal, calcified, encases vessels, crosses midline, ↑ urinary VMA/HVA.
12. VHL → bilateral clear-cell RCC; WAGR/Beckwith–Wiedemann → Wilms; T1a RCC → nephron-sparing partial nephrectomy.